Skip to main content

Table 1 Baseline patient demographics and clinical data

From: The effectiveness of topical colloidal silver in recalcitrant chronic rhinosinusitis: a randomized crossover control trial

 

Group 1 (n = 8)

Group 2 (n = 12)

Mean age (range in years)

65.8 (44–86)

62.3 (45–84)

Female, n (%)

6 (75.0)

2 (16.7)

CRS symptoms ≤5 years, n (%)

1 (12.5)

2 (16.7)

CRS symptoms 6 or more years, n (%)

7 (87.5)

10 (83.3)

Current smoker, n (%)

0 (0)

0 (0)

Past smoker, n (%)

3 (37.5)

4 (33.3)

Asthma, n (%)

3 (37.5)

4 (33.3)

Environmental allergies, n (%)

6 (75.0)

6 (50.0)

Number of surgeries, mean (SD)

2.5 (1.9)

3.1 (2.5)

Current topical saline irrigation, n (%)

7 (87.5)

12 (100.0)

Oral steroid use last 12 months, n (%)

7 (87.5)

10 (83.3)

Oral steroid use during study, n (%)

1 (12.5)

1 (8.3)

Oral antibiotic use last 12 months, n (%)

8 (100.0)

11 (91.7)

Oral antibiotic use during study, n (%)

1 (12.5)

0 (0.0)

Baseline SNOT-22 score, mean (SD)

59.3 (19.4)

52.8 (19.2)

Baseline LK score, mean (SD)

7.8 (2.2)

6.8 (2.3)

  1. CRS chronic rhinosinusitis, SD standard deviation, SNOT-22 Sino Nasal Outcome Test, LK- Lund-Kennedy